Gains_NN
made_VBN [WZPAST]
by_PIN
Directors_NN
on_PIN
share_NN
options_NOMZ
and_PHC
LTIPs_NN
audited_VBD
The_DT
table_NN
below_PLACE
shows_NN
gains_NN
made_VBN [WZPAST]
by_PIN
individual_JJ
Directors_NN
from_PIN
the_DT
exercise_NN
of_PIN
share_NN
options_NOMZ
and_PHC
LTIPs_NN
._.
The_DT
gains_NN
are_VPRT [PASS]
calculated_VBN [PRIV]
as_IN
at_PIN
the_DT
exercise_NN
date_NN
,_,
although_CONC
the_DT
shares_NN
may_POMD
have_VB [PEAS]
been_VBN [PASS]
retained_VBN
._.
2002 2001 000 000_CD
Dr_NN
John_NN
Brown_NN
89_CD
330_CD
Gordon_NN
Cameron_NN
585_CD
-_:
Nicolas_NN
Higgins_NN
16_CD
343_CD
Total_JJ
gains_NN
on_PIN
share_NN
options_NOMZ
&_CC
LTIPs_NN
690_CD
673_CD
Acambis_NN
Total_NN
Shareholder_NN
Return_NN
TSR_NN
performance_NN
Acambis_NN
TSR_NN
performance_NN
is_VPRT [PASS]
shown_VBN [PRIV]
against_PIN
the_DT
FTSE_NN
All-Share_NN
Pharmaceuticals_NN
&_CC
Biotech_NN
Index_NN
._.
This_DEMO
index_NN
has_VPRT [PEAS]
been_VBN [PASS]
chosen_VBN
as_IN
Acambis_NN
is_VPRT [BEMA]
a_DT
constituent_NN
of_PIN
this_DEMO
sector_NN
._.
31_CD
December_NN
1997_CD
0_CD
On_PIN
behalf_NN
of_PIN
the_DT
Board_NN
Alan_NN
Dalby_NN
,_,
Non-executive_JJ
Director_NN
27_CD
March_NN
2003_CD
63_CD
